Trials / Recruiting
RecruitingNCT06021483
Observational Study to Evaluate the Safety and Efficacy of Zepzelca™ Injection
Observational Study to Evaluate the Safety and Efficacy of Zepzelca™ Injection (Lurbinectedin) in Patients With Metastatic Small Cell Lung Cancer (SCLC) in Real-World Practice
- Status
- Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 300 (estimated)
- Sponsor
- Boryung Pharmaceutical Co., Ltd · Industry
- Sex
- All
- Age
- 19 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the safety and efficacy of Zepzelca™ inj. in real-world practice and to investigate important identified risks and gaps in information related to risk management plans.
Conditions
Timeline
- Start date
- 2023-08-16
- Primary completion
- 2025-09-01
- Completion
- 2025-09-01
- First posted
- 2023-09-01
- Last updated
- 2025-09-16
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT06021483. Inclusion in this directory is not an endorsement.